226 related articles for article (PubMed ID: 38289576)
1. Intratumoral Injection of Large Surface Area Microparticle Taxanes in Carcinomas Increases Immune Effector Cell Concentrations, Checkpoint Expression, and Synergy with Checkpoint Inhibitors: A Review of Preclinical and Clinical Studies.
diZerega GS; Maulhardt HA; Verco SJ; Marin AM; Baltezor MJ; Mauro SA; Iacobucci MA
Oncol Ther; 2024 Mar; 12(1):31-55. PubMed ID: 38289576
[TBL] [Abstract][Full Text] [Related]
2. Local administration of large surface area microparticle docetaxel to solid carcinomas induces direct cytotoxicity and immune-mediated tumoricidal effects: preclinical and clinical studies.
Maulhardt H; Verco S; Baltezor M; Marin A; diZerega G
Drug Deliv Transl Res; 2023 Feb; 13(2):503-519. PubMed ID: 36058988
[TBL] [Abstract][Full Text] [Related]
3. Phase 1/2 Trial Results of a Large Surface Area Microparticle Docetaxel for the Treatment of High-Risk Nonmuscle-Invasive Bladder Cancer.
Kates M; Mansour AM; Lamm DL; Shore N; Maulhardt H; Wendt A; Verco J; Marin A; Dewnani K; Verco S; diZerega GS
J Urol; 2022 Oct; 208(4):821-829. PubMed ID: 35574612
[TBL] [Abstract][Full Text] [Related]
4. Intratumoral Treatment of Melanoma Tumors with Large Surface Area Microparticle Paclitaxel and Synergy with Immune Checkpoint Inhibition.
Maulhardt HA; Marin AM; diZerega GS
Int J Nanomedicine; 2024; 19():689-697. PubMed ID: 38283196
[TBL] [Abstract][Full Text] [Related]
5. Submicron particle docetaxel intratumoral injection in combination with anti-mCTLA-4 into 4T1-Luc orthotopic implants reduces primary tumor and metastatic pulmonary lesions.
Maulhardt H; Marin A; Hesseltine H; diZerega G
Med Oncol; 2021 Jul; 38(9):106. PubMed ID: 34331595
[TBL] [Abstract][Full Text] [Related]
6. Response of Locally Advanced Pancreatic Cancer to Intratumoral Injection of Large Surface Area Microparticle Paclitaxel: Initial Report of Safety and Clinical Outcome.
Sharma NR; Lo SK; Hendifar A; Othman MO; Patel K; Mendoza-Ladd A; Verco S; Maulhardt HA; Verco J; Wendt A; Marin A; Schmidt CM; diZerega G
Pancreas; 2023 Mar; 52(3):e179-e187. PubMed ID: 37782888
[TBL] [Abstract][Full Text] [Related]
7. Intracystic injection of large surface area microparticle paclitaxel for chemoablation of intraductal papillary mucinous neoplasms: Insights from an expanded access protocol.
Krishna SG; Ardeshna DR; Shah ZK; Hart PA; Culp S; Jones D; Chen W; Papachristou GI; Han S; Lee PJ; Shah H; Pawlik TM; Dillhoff M; Manilchuk A; Cloyd J JM; Ejaz A; Fry M; Noonan AM
Pancreatology; 2024 Mar; 24(2):289-297. PubMed ID: 38238194
[TBL] [Abstract][Full Text] [Related]
8. Early phase trial of intracystic injection of large surface area microparticle paclitaxel for treatment of mucinous pancreatic cysts.
Othman M; Patel K; Krishna SG; Mendoza-Ladd A; Verco S; Abidi W; Verco J; Wendt A; diZerega G
Endosc Int Open; 2022 Dec; 10(12):E1517-E1525. PubMed ID: 36531683
[No Abstract] [Full Text] [Related]
9. MAC-321, a novel taxane with greater efficacy than paclitaxel and docetaxel in vitro and in vivo.
Sampath D; Discafani CM; Loganzo F; Beyer C; Liu H; Tan X; Musto S; Annable T; Gallagher P; Rios C; Greenberger LM
Mol Cancer Ther; 2003 Sep; 2(9):873-84. PubMed ID: 14555706
[TBL] [Abstract][Full Text] [Related]
10. Effects of Cinnamon (C. zeylanicum) Bark Oil Against Taxanes-Induced Damages in Sperm Quality, Testicular and Epididymal Oxidant/Antioxidant Balance, Testicular Apoptosis, and Sperm DNA Integrity.
Sariözkan S; Türk G; Güvenç M; Yüce A; Özdamar S; Cantürk F; Yay AH
Nutr Cancer; 2016; 68(3):481-94. PubMed ID: 27008095
[TBL] [Abstract][Full Text] [Related]
11. A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy.
Shirakawa T; Kato K; Nagashima K; Nishikawa A; Sawada R; Takahashi N; Shoji H; Sasaki Y; Honma Y; Iwasa S; Takashima A; Okita N; Hamaguchi T; Yamada Y; Shimada Y
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1207-15. PubMed ID: 25267597
[TBL] [Abstract][Full Text] [Related]
12. Activity of docetaxel in paclitaxel-resistant ovarian cancer cells.
Sato S; Kigawa J; Kanamori Y; Itamochi H; Oishi T; Shimada M; Iba T; Naniwa J; Uegaki K; Terakawa N
Cancer Chemother Pharmacol; 2004 Mar; 53(3):247-52. PubMed ID: 14610615
[TBL] [Abstract][Full Text] [Related]
13. In vivo evaluation of mucoadhesive nanoparticulate docetaxel for intravesical treatment of non-muscle-invasive bladder cancer.
Mugabe C; Matsui Y; So AI; Gleave ME; Baker JH; Minchinton AI; Manisali I; Liggins R; Brooks DE; Burt HM
Clin Cancer Res; 2011 May; 17(9):2788-98. PubMed ID: 21357680
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety Assessment of Paclitaxel in Patients with Docetaxel-Resistant Esophageal Squamous Cell Carcinoma.
Imai H; Komine K; Takahashi S; Saijo K; Okada Y; Kobayashi A; Okita A; Chikamatsu S; Kasahara Y; Takahashi M; Oishi T; Shirota H; Takahashi M; Shimodaira H; Ishioka C
Chemotherapy; 2016; 61(5):262-8. PubMed ID: 27043795
[TBL] [Abstract][Full Text] [Related]
15. Clinical benefit of switching from paclitaxel to docetaxel or vice versa in cutaneous angiosarcoma patients resistant to first taxane chemotherapy.
Yonekura S; Endo Y; Fujii H; Ishikawa M; Egawa G; Kabashima K
J Dermatol; 2023 Nov; 50(11):1493-1496. PubMed ID: 37400887
[TBL] [Abstract][Full Text] [Related]
16. Sensitizing the cytotoxic action of Docetaxel induced by Pentoxifylline in a PC3 prostate cancer cell line.
Cancino-Marentes ME; Hernández-Flores G; Ortiz-Lazareno PC; Villaseñor-García MM; Orozco-Alonso E; Sierra-Díaz E; Solís-Martínez RA; Cruz-Gálvez CC; Bravo-Cuellar A
BMC Urol; 2021 Mar; 21(1):38. PubMed ID: 33711972
[TBL] [Abstract][Full Text] [Related]
17. A retrospective comparison of docetaxel and paclitaxel for patients with advanced or recurrent esophageal cancer who previously received platinum-based chemotherapy.
Mizota A; Shitara K; Kondo C; Nomura M; Yokota T; Takahari D; Ura T; Muro K
Oncology; 2011; 81(3-4):237-42. PubMed ID: 22094594
[TBL] [Abstract][Full Text] [Related]
18. Chitosan-based advanced materials for docetaxel and paclitaxel delivery: Recent advances and future directions in cancer theranostics.
Ashrafizadeh M; Ahmadi Z; Mohamadi N; Zarrabi A; Abasi S; Dehghannoudeh G; Tamaddondoust RN; Khanbabaei H; Mohammadinejad R; Thakur VK
Int J Biol Macromol; 2020 Feb; 145():282-300. PubMed ID: 31870872
[TBL] [Abstract][Full Text] [Related]
19. Androgen receptor negatively regulates mitotic checkpoint signaling to induce docetaxel resistance in castration-resistant prostate cancer.
Pilling A; Kim SH; Hwang C
Prostate; 2022 Feb; 82(2):182-192. PubMed ID: 34672379
[TBL] [Abstract][Full Text] [Related]
20. Exploring the Promising Potential of High Permeation Vesicle-Mediated Localized Transdermal Delivery of Docetaxel in Breast Cancer To Overcome the Limitations of Systemic Chemotherapy.
Bathara M; Date T; Chaudhari D; Ghadi R; Kuche K; Jain S
Mol Pharm; 2020 Jul; 17(7):2473-2486. PubMed ID: 32496783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
